Startups

Shionogi logo

Shionogi

Osaka, Japan

shionogi.com

Shionogi & Co., Ltd. is the Osaka-headquartered Japanese pharmaceutical parent company, established March17,1878 and incorporated June5,1919. It researches, develops, manufactures and distributes medicines, diagnostic reagents and medical devices, with programs in infectious diseases, neuroscience, pain and rare diseases. Its digital-health work includes Akili-derived ADHD therapeutics and AI-supported drug discovery. Shionogi also makes strategic corporate investments: issuer filings confirm an actual USD5M cash corporate bond to Akili in March2019, distinct from licensing payments, royalties, contingent milestones and later equity transactions. The company established an internal Corporate Venture Capital group in April2025, investing across healthcare technologies and value-chain innovations in Japan, the US, Europe and Asia. Its disclosed FY2025 USD7M setup/investment budget and approximately USD14M planned annual budget are corporate allocations, not closed outside-LP venture funds. The current primary company directory publishes 27 unique directors and corporate officers; its CVC page additionally names six investment-team members, all included here. Isao Teshirogi is representative director, president and CEO; independent outside director Keiichi Ando chairs the board. This profile represents Shionogi & Co., Ltd., not its separate Shionogi Inc. US company, European companies, Shionogi Healthcare retail subsidiary or an independently assumed fund manager. Paid-in capital, operating revenue and licensing budgets are not new funding rounds. Shionogi is listed on the Tokyo Stock Exchange Prime Market under securities code4507. Its current pipeline includes investigational conversational AI cognitive-function testing SDS-881 with FRONTEO and neuroscience drug candidates; a research or licensing collaboration is not automatically an equity investment. In March2026 it obtained two distinct unsecured corporate bridge loans from Sumitomo Mitsui Banking Corporation: JPY360B for acquiring edaravone/RADICAVA rights and JPY300B for additional ViiV equity. These are company debt financings, not venture funds; the JPY660B total is not a third raise.

Team

Akira KatoSenior Executive Officer, Senior Vice President, Supply Supervisory Unit
Emi KatoEmi KatoCVC Group, Corporate Planning Dept., Corporate Strategy Div.
Fumi TakatsukiFumi TakatsukiOutside Director (Member of the Audit and Supervisory Committee)
Haruyo KonishiHaruyo KonishiCVC Group, Corporate Planning Dept., Corporate Strategy Div.
Hiroshi OzakiHiroshi OzakiOutside Director
Isao TeshirogiIsao TeshirogiRepresentative Director, President and CEO
John KellerJohn KellerDirector and Senior Executive Officer, Senior Vice President, R&D Supervisory Unit
Kazuhiro HatanakaSenior Executive Officer, Senior Vice President, Corporate Supervisory Unit
Kazuyuki SaitoKazuyuki SaitoCVC Group, Corporate Planning Dept., Corporate Strategy Div.
Keiichi AndoKeiichi AndoOutside Director (Chairperson of the Board of Directors)
Keiichi YoshiiKeiichi YoshiiOutside Director
Keisuke KusumotoKeisuke KusumotoGeneral Manager, CVC Group, Corporate Planning Dept., Corporate Strategy Div.
Kenji MatsuoCorporate Officer, Vice President, Internal Control Department
Kensuke MatsumuraKensuke MatsumuraCVC Group, Corporate Planning Dept., Corporate Strategy Div.
Koji HanasakiKoji HanasakiDirector (Member of the Audit and Supervisory Committee)
Kyoko HiroseKyoko HiroseOutside Director
Li JiangLi JiangCVC Group, Corporate Planning Dept., Corporate Strategy Div.
Masako KudouCorporate Officer, Senior Vice President, Corporate Strategy Division
Masashi DeguchiCorporate Officer, Senior Vice President, Sustainability Management Division
Noriyuki KishidaNoriyuki KishidaDirector (Member of the Audit and Supervisory Committee)
Satoru YoshimotoCorporate Officer, Senior Vice President, Integrated Disease Care Division
Shuichi OkuharaShuichi OkuharaOutside Director (Member of the Audit and Supervisory Committee)
Takaoki FujiwaraTakaoki FujiwaraOutside Director
Takeki UeharaCorporate Officer, Senior Vice President, Drug Development and Regulatory Science Division
Takeshi ShiotaCorporate Officer, Senior Vice President, Corporate Quality Assurance and Ethics & Compliance Management Division
Tatsumori YoshidaCorporate Officer, Senior Vice President, Pharmaceutical Technology Research Division
Tetsuya NumaCorporate Officer, Senior Vice President, Vaccine Business Division
Toshinobu IwasakiSenior Executive Officer, Senior Vice President, Healthcare Business Supervisory Unit
Toshiyuki AsakiCorporate Officer, Senior Vice President, Drug Discovery Research Division
Yasuyoshi IsoCorporate Officer, President, Shionogi Pharma Co., Ltd.
Yoriko GotoYoriko GotoOutside Director (Chairperson of the Audit and Supervisory Committee)
Yoshinori YurugiCorporate Officer, Senior Vice President, Pharmaceutical Commercial Division
Yousuke MiharuCorporate Officer, Senior Vice President, DX Promotion Division

Investments